Welcome to our dedicated page for Bolt Biotherapeutics SEC filings (Ticker: BOLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bolt Biotherapeutics SEC filings document the company’s public-company governance, financial-results reporting, and clinical-stage oncology disclosures. Recent Form 8-K reports furnish quarterly and annual results and business updates for BDC-4182 and the Boltbody™ ISAC platform, while proxy materials describe director elections, auditor ratification, and stockholder meeting mechanics.
The filing record also includes emerging growth company status, restructuring disclosures under exit or disposal activity rules, estimated severance and benefit costs, and updates on pipeline and capital-preservation measures. These filings frame Bolt’s governance procedures, operating expense controls, reporting status, and development-stage business disclosures as a Nasdaq-listed biopharmaceutical issuer.
Bolt Biotherapeutics, Inc. reported that one of its directors entered into several option transactions on 12/12/2025. The director cancelled previously granted stock options with higher exercise prices and received new director stock options with an exercise price of $5.44 per share for the same numbers of underlying common shares.
One option grant for 2,500 shares expiring in 2032 vests in equal monthly installments from December 14, 2022 until the third anniversary of that date, while other grants reported are already fully vested and exercisable. Another 1,100-share option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, and certain of these options vest in full upon a change in control of the company.
A director of Bolt Biotherapeutics, Inc. reported multiple option transactions dated December 12, 2025 involving director stock options on Bolt common stock. The director canceled several existing stock options and received new director stock options over the same numbers of shares, with each exchange recorded as a disposal and a corresponding acquisition.
In each case, the existing option was canceled in exchange for a new option with a lower exercise price of $5.44. One new option covering 1,100 shares will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the director’s continuous service, and will vest in full upon a change in control of Bolt Biotherapeutics.
Bolt Biotherapeutics, Inc. director reported multiple stock option changes dated December 12, 2025. The reporting person agreed to cancellation of existing director stock options that had higher exercise prices such as $180.2, $60.6, $39.8, $32.6, $15.364 and $6.4 in exchange for new options having a lower exercise price of $5.44 per share. These new options cover blocks of common stock, including 1,393 and 1,810 shares. One new option for 1,100 shares will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, and will vest in full upon a change in control of the company.
Bolt Biotherapeutics reported insider equity activity involving its Senior VP, Finance and PAO, with an earliest transaction date of 12/12/2025. The filing covers a series of employee stock options on common stock.
The executive agreed to cancel multiple existing stock options granted between 2020 and 2025 in exchange for new employee stock options with a lower exercise price of $5.44 per share, in blocks such as 1,236, 375, 600, 2,199, 6,699, 1,589, 2,499, 4,499 and 11,299 shares. Some replacement options vest in equal monthly installments of 1/36th of the shares, so long as the executive continues providing services, with vesting schedules beginning after dates including January 1, 2023, January 1, 2024, July 15, 2024 and January 1, 2025. At least one option is already fully vested and exercisable.
Bolt Biotherapeutics, Inc. reported that its Chief Operating Officer adjusted multiple employee stock options on 12/12/2025. Existing options with higher exercise prices were cancelled, and new employee stock options with a $5.44 exercise price and the same share amounts and expiration dates were granted in exchange.
One of the new options is fully vested and exercisable. Several other new options vest in equal 1/36th installments each month after specified dates in 2023, 2024 and 2025, for so long as the reporting person continuously provides services to the company.
Bolt Biotherapeutics reported changes to a senior insider’s equity compensation on December 12, 2025. The reporting person is a director who also serves as President, CEO and CFO, and the transactions involve employee stock options to purchase common stock.
Several existing stock option grants with higher exercise prices were cancelled in exchange for new employee stock options with an exercise price of $5.44 per share. One of the options is fully vested and exercisable, while multiple new options vest in 36 monthly installments as long as the reporting person continues providing services, with vesting schedules starting from dates such as January 1, 2023, January 1, 2024, July 15, 2024, and January 1, 2025.
Bolt Biotherapeutics filed its Q3 2025 10‑Q, reporting collaboration revenue of $2.169 million and a quarterly net loss of $7.144 million (basic and diluted net loss per share $3.72). Operating expenses were $9.872 million, reflecting lower R&D and G&A versus the prior year. Other income was $0.559 million, aided by interest.
As of September 30, 2025, cash, cash equivalents and marketable securities totaled $38.8 million, with total assets of $65.053 million and stockholders’ equity of $32.101 million. Management states these resources may be sufficient to fund operations into 2027, yet concluded there is substantial doubt about continuing as a going concern within one year of issuance, given dependence on collaboration income and additional financing.
The company implemented cost controls, including subleasing facilities and prior workforce reductions, and on October 1, 2025 announced a new restructuring to cut about 20 employees (~50%), with estimated charges of $1.5–$2.0 million to be recorded in Q4 2025. A 1‑for‑20 reverse stock split was effected on June 6, 2025. Shares outstanding were 1,919,441 as of November 5, 2025.
Bolt Biotherapeutics (BOLT) furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025 and a corporate update. The press release is attached as Exhibit 99.1 and incorporated by reference.
The company states the information is furnished, not filed, and therefore is not subject to Section 18 liability under the Exchange Act nor automatically incorporated into other SEC filings.
Bolt Biotherapeutics (BOLT) insider activity: the company’s Senior VP, Finance and PAO reported two transactions. On June 6, 2025, the officer purchased 125 shares of common stock at $5.492, acquired under the Employee Stock Purchase Plan. On October 22, 2025, the officer received 23,000 restricted stock units for no consideration; each RSU represents one share upon settlement and will vest in full on September 15, 2026, assuming continued employment. Following these transactions, direct beneficial ownership stands at 23,943 shares.
Bolt Biotherapeutics (BOLT) reported an insider equity award. The Chief Operating Officer received 30,000 restricted stock units for no consideration on 10/22/2025. Each RSU represents the right to receive one share of common stock at settlement.
The award will vest in full on September 15, 2026, assuming continued employment through that date. Following the reported transaction, the officer beneficially owned 38,918 shares of common stock, held directly.